AIM2 and renal carcinoma: To further validate our hypothesis that H1/AIM2 could suppress the migration and invasion of RCC by enhancing the inflammasome activation, renal cancer cells was treated with H1/pAIM2 nanoparticles followed with or without the downstream inflammatory caspase inhibitors YVAD‐CMK.